Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
NLS Pharmaceutics AG - SIC # 2830 -
Ticker
Exchange
SIC #
Website
Latest Ticker
NLSP
Nasdaq
2830
nlspharma.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for NLS Pharmaceutics AG
NLS Pharmaceutics and Kadimastem Unveil Multi-Target Approach to Diabetes, Expanding Beyond GLP-1 Therapies
- Feb 10th, 2025 12:30 pm
Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics
- Jan 31st, 2025 12:30 pm
NLS Pharmaceutics Announces the Submission of Three Research Abstracts to the 2025 ASCP Annual Meeting
- Jan 30th, 2025 12:30 pm
NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence
- Jan 28th, 2025 12:30 pm
Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS
- Jan 16th, 2025 2:32 pm
NLS Pharmaceutics and Kadimastem Advance Merger Plans with $500,000 Fundraising
- Jan 9th, 2025 1:28 pm
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce the Initial Closing of $500,000 of the Previously Announced $1 Million Fundraising by NLS Following its Extraordinary General Meeting at a Share Price of $3.10, Representing 48% Above the Market Share Price as of Jan 6, 2025
- Jan 8th, 2025 12:42 pm
NLS Pharmaceutics Ltd. and Kadimastem Ltd. Announce Filing of F-4 Registration Statement with the SEC Ahead of Proposed Merger
- Dec 30th, 2024 12:30 pm
NLS Pharmaceutics and Kadimastem Announce the Submission of a Request by Kadimastem and iTolerance, Inc. for an FDA Pre-IND Meeting for an Innovative Breakthrough Type 1 Diabetes Treatment
- Dec 19th, 2024 12:30 pm
NLS Pharmaceutics expects to close Kadimastem merger by end of January
- Dec 12th, 2024 12:45 pm
NLS Pharmaceutics CEO Issues Letter to Shareholders
- Dec 11th, 2024 12:30 pm
NLS Pharmaceutics Ltd. Announces Pricing of Private Placement of up to $1 Million at a 15% Premium to the Market
- Dec 4th, 2024 6:15 pm
NLS Pharmaceutics Announces Promising Preclinical Data for First-in-Class Non-Sulfonamide, Dual Orexin Receptor Agonists for the Potential Treatment of Narcolepsy and Neurological Disorders
- Dec 3rd, 2024 12:40 pm
NLS Pharmaceutics Highlights Innovative Preclinical Program for First-in-Class Non-Sulfonamide Dual Orexin Receptor Agonists (DOXA) in Narcolepsy and Neurological Disorders
- Nov 18th, 2024 12:30 pm
NLS and Kadimastem stocks soar following merger agreement
- Nov 5th, 2024 5:53 pm
NLS Pharmaceutics, Kadimastem enter definitive merger agreement
- Nov 5th, 2024 12:31 pm
NLS Pharmaceutics and Kadimastem Enter into a Definitive Merger Agreement
- Nov 4th, 2024 12:00 pm
NLS Pharmaceutics Ltd. Regains Full Compliance with Nasdaq Listing Requirements
- Oct 28th, 2024 11:00 am
NLS Pharmaceutics Secures Key Patent in Japan for Mazindol ER in the Treatment of Heroin Dependence
- Oct 21st, 2024 11:00 am
NLS Pharmaceutics Ltd. Announces Closing of Private Placement and Expected Compliance with Nasdaq Continued Listing Rules
- Oct 15th, 2024 11:00 am
Scroll